From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Folic Acid, B Vitamins, and Heart Disease in Women

No evidence shows that supplementation is beneficial, despite lower homocysteine levels.

In observational studies, homocysteine levels are associated with cardiovascular risk. However, randomized trials have not confirmed that homocysteine-lowering therapy (with folic acid and vitamins B6 and B12) reduces cardiovascular risk, perhaps because the trials were too short to evaluate this outcome. In addition, women have been underrepresented in these trials. To remedy these methodologic deficiencies, researchers conducted a 7-year, randomized, controlled trial that involved 5442 women (age, ≥40; mean age, 62) with known cardiovascular disease (CVD) or at least three major CVD risk factors.

Intervention subjects received folic acid (2.5 mg), vitamin B6 (50 mg), and vitamin B12 (1 mg) daily. During 7 years of follow-up, adverse CVD events (myocardial infarction, stroke, coronary revascularization, or cardiac death) occurred in 14.9% of intervention patients and in 14.3% of controls — a nonsignificant difference. In addition, no significant differences were found in analyses of specific outcomes. The mean homocysteine level was lowered by roughly 19% in the intervention group.

Comment: These data are consistent with those of other randomized trials. The study is larger and longer than past trials, and these results appear to resolve the uncertainty about whether such supplementation benefits women, who had been underrepresented previously. Recommending folic acid and B vitamin supplementation to lower risk in patients at high risk for CVD has no basis.

Thomas L. Schwenk, MD

Published in Journal Watch General Medicine May 6, 2008

Citation(s):

Albert CM et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008 May 7; 299:2027.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Other Perspectives

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2008. Massachusetts Medical Society. All rights reserved.